Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Should be
If u don’t think has Dollars written all over this …you’re clueless…
Nice finish. Have a great.
Weekend everyone.
Patience is Everything! I Believe the Tables have Changed to Steady Upward Movement here. I couldn’t say that 2 months ago!
Yes and actually I think the chart is looking great since April 10th...it wants released...but will it without the proper news...it might!
Imo, i don't see anything next week specifically, apart from something (new) announced after the ONS Congress (that's ending on Sunday 28).
If they'll present PIII results at ASCO, then why no abstract on ASCO site? That's what intrigues me. Especially after delaying completion date to June (from april, iirc).
Also, technicals don't mean anything without some news coming. The daily chart is clearly extremely bullish, but that's expected given the upcoming catalyst(s). I 100% agree it's charged and ready to rocket on good news, question is when.
Higher Lows Higher Highs. News will send this to $.30-$.40 on 1 Session alone.
Pinky are looking at the 5 Day Chart? Next Week it’s on!
LOL...he may have but I believe it was for me or whoever he thought needed to do their own DD and who lives under a rock...LOL...he posted directly after I asked him to refresh my memory why next week might be so important.
He meant for me lol!! I m a naive trader🤪
No actually I do not live under a rock...as for DD I am aware of the R/S that was voted in on April 8th....I am aware of the extension with the SEC to get this back over a dollar before August 13th 2024...and I am aware that the test results of the phase 3 trial are soon to be announced for the product Crofelemer/Prophylaxis...I was also aware of the ASCO conference, but I forgot about it or didn't put much thought into it because I really don't see nothing big coming from it as though some big break through announcement is going to be made because of it....but it might.
and it closed over .18 phahahahahahah! I just watched a battle on L2 data. Shorts are TRIGGERED
Interesting indeed
I saw this on stocktwits and wanted to share. This is my belief in JAGX:
$JAGX by preventing Chemi related diarrhea with Crofelemer (Myresi), patients may have more stable drug levels in their bodies, potentially increasing the effectiveness of chemotherapy and reducing the likelihood of tumor drug resistance.
That’s why I buy and hold. Cause it’s not about just my wallet. It’s something that I believe is like nothing else on the market and is desperately needed. Let’s get after it bulls! - Smartwinner
I'd like to offer a suggestion, since it has helped me maintain my focus of being a positive and well informed person in this board. If you see individuals in here who are bashing/negative/UNINFORMED/NO-DD, simply ignore the user :D
Reloading zone .184
Are you Living under Rock? Do your DD It’s All Available
Refresh my memory...what happens next week?
Why? U have insider info????? Please share with us!!
If your holding and Sell now before next week Your Crazy!
Hot .195 than back down😛
Has the momentum to close in the 2s today
JAGX
Maybe partnership or contract news on da way?
I want .2!! Please
JAGX breaking out leaving the station
JAGX
Help me understand something. How can they be present at ASCO (we know this because NAPO has a stand there) but no abstract is present on ASCO site till this moment? It's already 26th, other abstracts were uploaded on 24th. What's their plan?
Grabbed some 172 in the channel lets see what happens :)
JAGX
Yessir! Tables have Changed! New Beginning. IMO
Timing is everything and it's JAGX's biggest chess piece :)
I Anticipate PR Release Before or After Market Today or Monday. Conference is 24th-28th Something Should Come of it. Would be Silly to Unload Shares now. This is a Hold and Buy as this has Big Leg Up Coming! IMO
Low Volume on a Friday
Always the pre market attack
Based on the value of the drug, and knowing we are international (not only US based), and knowing we are working with partnerships (no buy out) , their market capacity can easily grow into multi billion dollars over some years...
For 2024 and positive P3 data, I guess 1 billion market cap can and must be the goal
this puts us between 3 and 4 dollar without further dilution
That makes no sense when it comes to valuing a company.
Golden Cross occurred for the second time in 2 days, the month chart is super tight the bollinger bands are getting ready to close
It's getting tight just needs a catalyst.
We already knew they will be present at ONS. But i don't think they'll present PIII results now, it makes no sense with them moving up the completion date of the study to 06/2024, just a couple of weeks ago.
$JAGX here is Jaguar/Napo exhibit at Oncology Nursing Conference! https://t.co/pUabVcSqCm pic.twitter.com/15LkndVtbe
— Doctor DD (@TheOnlyRampart1) April 25, 2024
lowest volume morning in a month.... buy when its ugly
Let's see who makes the next move, there is no way JAGX doesn't know they're being shorted. It's all about timing and facts, everything else is just noise.
Those borrow fees have been 60% for days and they barely moved the price...
When JAGX had it's highest volume day EVER of 650,000,000 , there was over 298,000,000 dark pool short volume. Unfathomable numbers to think about.
Followers
|
149
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6000
|
Created
|
12/01/15
|
Type
|
Free
|
Moderators ProfitChaser oldstocks DTGoody powerbattles SmellMyFinger |
Jaguar Health, Inc. $JAGX
Bringing Plant-based Medicines to Life™
Pharmaceutical Manufacturing
San Francisco, California
Jaguar Health’s organizational framework is designed to enable our product pipeline to reach the world’s interconnected marketplace, allowing for development and commercialization opportunities worldwide.
Products:
Mytesi Crofelemer 125mg delayed release tablets
Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
Market size of the FDA HIV Mytesi Crofelemer could be $25-$30 Million in the USA
Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea.
Mytesi is not indicated for the treatment of infectious diarrhea. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).
Canalevia-CA1 Crofelemer delayed release tablets
Distributors listed:
https://www.canalevia.com/distributor-information
CANALEVIA-CA1 is conditionally approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.
Lytham Partners Investor Select Conference February 1st, 2024
https://wsw.com/webcast/lytham10/jagx/2084640
Pipeline: https://jaguar.health/pipeline/
How to calculate the value of drugs and biotech companies
https://www.baybridgebio.com/drug_valuation.html
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study , a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative is focused on developing novel prescription medicines derived from plants for mental health indications.
A Case Report: Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea
Despite the efficacy of tyrosine kinase inhibitors (TKIs) across multiple cancers, side effects including treatment-related diarrhea can impede a patient’s ability to reach therapeutic doses or stay on therapy.
Below, we present the case of a 72-year-old patient with metastatic papillary renal cell carcinoma recurrent despite nephrectomy.
Over the course of treatment, the patient received multiple different tyrosine kinase inhibitors with varying efficacy.
Treatment with the TKI cabozantinib after failure of two prior TKIs resulted in a clinical response with shrinkage of his nodal metastatic disease.
However, the severe treatment-related diarrhea refractory to conventional management required both dose holds and dose reductions of cabozantinib.
Off-label administration of crofelemer, a novel FDA-approved antidiarrheal agent, successfully controlled the treatment-related diarrhea and allowed resumption and partial dose increase of cabozantinib.
This case suggests that crofelemer could be a viable therapeutic strategy to address TKI-induced diarrhea.
9.8 million people
receive chemotherapy worldwide per year
Wilson B, Jacob S, Yap M, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769-780. doi:10.1016/S1470-2045(19)30163-9
Chemotherapy-induced
diarrhea occurs in
50%-80%
of treated patients
Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51-63. doi:10.1177/1758834009355164
Patients with cancer therapy–
related diarrhea (CTD) were
40% more likely to
discontinue chemotherapy or
targeted cancer therapy than
patients without CTD
Okhuysen PC, Schwartzberg LS, Roeland E, et al. The impact of cancer-related diarrhea on changes in cancer therapy patterns. J Clin Oncol. 2021;39(15):12111. doi:10.1200/JCO.2021.39.15_suppl.12111
Research & Development
In October 2020, Napo Pharmaceuticals initiated a pivotal Phase 3 clinical trial
This Phase 3 study is evaluating crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy
The principal investigator and co-investigators identified are from MD Anderson Cancer Center
Jaguar Health https://jaguar.health/
Napo Pharmaceuticals https://napopharma.com/
Napo Therapeutics https://napotherapeutics.com/en/
https://www.magdalenabiosciences.com/
Magdalena is a joint venture formed by Jaguar Health and Filament Health. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications.
Visit Jaguar on LinkedIn:
https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Phone: 415-371-8300
Contact: hello@jaguar.health
Press Releases: https://jaguarhealth.gcs-web.com/news-releases
Most if not all works by mechanism chloride ions into the gut then water comes and diarrhea out. Crofelemer normalizes abnormal ion flow targeting only locally in the gut.
Jaguar has been putting the expense into making sure Crofelemer drug supply is ready to get into this opportunity to treat cancer related chemo patients since pharmacy’s already can get FDA approved, all ready in the in the supply chain in the pharmacy as Crofelemer for AIDs patients.
Research has shown it costs 3x as much to treat a cancer patient with diarrhea.
It would be better to treat the cancer patient for diarrhea with Crofelemer pending OnTarget Study and FDA approval.
Since Crofelemer is FDA approved to treat dogs for Cancer Chemo related Diarrhea it has been said:
If your going to have cancer and cancer related Diarrhea, it’s better to be a dog than a human right now.
The companies that manufacture the cancer agents/drugs sort of point to the availability of Crofelemer because it allows them to keep their patients on their therapies thereby improving their penetration and their revenues opportunity.
3rd party market research put Short Bowel Syndrome at $5-$12 Billion opportunity because these patience are so ill, high mortality, high morbidity (the state of being unhealth for a particular disease or situation), so high of expense to manage through life.
That opportunity can be reached in small trials around the world to show benefits to be able to show global development.
Product already approved, already fully in the supply chain in the pharmacy.
Potential Market of Mytesi (crofelemer)
Jaguar and Napo $JAGX if the Phase 3 OnTarget Study has good results.
The Phase 3 OnTarget Study results are due to be out soon in this quarter.
The Phase 3 OnTarget study is testing whether the company's plant-based prescription drug crofelemer can prevent or substantially reduce diarrhea and other symptoms of CIOB when any one of the selected 24 different targeted therapies that are associated with diarrhea in patients is initiated.
Each year, more than 1 million cancer patients in the United States receive chemotherapy or radiation. Globally 9.8 million require chemotherapy.
Diarrhea is a common side effect of targeted therapies. Up to 95% of patients on tyrosine kinase inhibitors (TKIs) suffer from diarrhea, depending on the TKI used.
Any drug used to treat cancer (including tyrosine kinase inhibitors or TKIs) can be considered chemo, but here chemo is used to mean treatment with conventional cytotoxic (cell-killing) drugs that mainly kill cells that are growing and dividing rapidly. Chemo was once one of the main treatments for CML.
The cost for Mytesi oral delayed release tablet 125 mg is around $2,600 for a supply of 60 tablets. This amount is the one month supply as testing in the OnTarget Study.
That is a 24 week study = 5.6 month supply needed = $14,560.00 for treatment.
Potential Market of Mytesi (crofelemer)
100,000 patients a year = $1,456,000,000
250,000 patients a year = $3,640,000,000
500,000 patients a year = $7,280,000,000
1,000,000 patients a year = $14,560,000,000 (assuming worldwide)
5,000,000 patients a year = $72,800,000,000 (assuming worldwide)
The estimate of patients depends on how many quit taking chemo, the onTarget Study, FDA approval and or quit taking Mytesi (crofelemer).
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |